Why the study?
Does flecainide prevent recurrent ventricular fibrillation in children with compound heterozygous triadin mutations?
Does flecainide prevent recurrent ventricular fibrillation in children with compound heterozygous triadin mutations?
Flecainide may be an effective therapy for preventing recurrent ventricular fibrillation in young patients with compound heterozygous triadin mutations who are refractory to beta-blockers.
May support flecainide in refractory triadin-mutation VF; hypothesis-generating and requires prospective validation before practice change.
We present the case of two siblings who both presented with an out-of-hospital cardiac arrest at 2 years of age. Both siblings underwent internal cardiac defibrillator implantation and both had recurrent episodes of ventricular fibrillation (VF). A compound heterozygous mutation in the triadin gene was discovered; one of these mutations has been described previously in the homozygous state, and the other one is unreported. The combination of these mutations has resulted in a particularly arrhythmogenic phenotype, with cardiac arrest occurring at a very young age and recurrent episodes of VF despite β-blockade. Flecainide seems to have been very effective in preventing clinical arrhythmias for this particular mutation.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: